INS and Hyperglycemia: Diosmin reduced hyperglycemia by enhancing the secretion of β-endorphin from the adrenal glands via imidazoline 1–2 receptor (I-2R) activation, which triggered the opioid receptors to attenuate gluconeogenesis metabolism in the livers of diabetic rats. It decreased the hepatic glycogen content and plasma lipid profiles in STZ-induced diabetic rats. However, it did not adversely affect the body weight, food intake, and plasma insulin level in the diabetic rats.